It is amazing how MultiplexDX is developing from a small startup into a truly influential company, capable of shaking up the old biotech market with its revolutionary innovations. Although it is less than 2 years since its founding, MultiplexDX has won more than 15 prestigious awards, grants, and coveted placements in special programs as well as significant media and investor attention. This pattern of success continued this summer when MultiplexDX received a €176 000 grant from the Ministry of Education of the Slovak Republic.
Dr. Peter Kilian, founder and COO of MultiplexDX, comments:
"It was a very pleasant surprise for us to get this significant support from the government. We are proud to be chosen from more than 270 projects and very thankful for this great opportunity! With such a substantial support, both from the government and private investors from around the world, we will do our best to bring MultiplexDX innovations to the market as soon as possible and help thousands of people to beat cancer!"
This governmental grant will also help to approach key opinion leaders (oncologists) and medical students who need the information about the latest oncology diagnostic opportunities for their work. The MultiplexDX team would like to emphasize the importance of personalized diagnostics and make an educational video about the origin of cancer, the importance of biomarkers in tumor identification and characterization, conventional and state-of-the-art diagnostic methods and other important topics. That's is a nice way not only to educate the industry professionals but also to build up the trustful partnership relations in the future.
The Ministry of Education, Science, Research and Sports of the Slovak Republic (MESRS) is the most important government body in the field of science and technology (S&T), human resources, life-long learning and higher education. The ministry supports basic and applied research via state budget allocations and competitive grants. Applied research also is supported via public procurement and carried out by (private) industry research institutes. In 2014-2020 programming period the ministry is the managing authority of the Operational Programme Research and Innovation.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
